Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

GPR152 Receptor Antibodies

Close filters
No results were found for the filter!
NEW
GPR152 (non-phospho), G protein-coupled Receptor 152 Antibody
GPR152 (non-phospho), G protein-coupled...
The non-phospho-GPR152 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human GPR152. It can be used to detect total GPR152 receptors in Western blots independent of phosphorylation. The GPR152...
375.00 € *
GPR152 is an orphan class A GPCR for which the endogenous ligand, physiological signaling pathway and pharmacological function remain largely unresolved. The receptor is predominantly expressed in the central nervous system, with detectable expression in several brain regions and particularly in neuronal populations involved in metabolic and neuroendocrine regulation. GPR152 has also been detected in peripheral tissues, although its expression outside the CNS is comparatively poorly characterized. Available studies suggest that the receptor may couple to Gi/o and/or Gq/11 proteins, but these signaling assignments have not been sufficiently validated. Functional evidence indicates that GPR152 may participate in the regulation of neuronal signaling, energy homeostasis and endocrine functions, although a definitive physiological role has not yet been established. Genetic and expression studies have generated interest in GPR152 in the context of metabolic disorders and potentially CNS diseases, but the available evidence remains preliminary. No endogenous ligand has been conclusively identified, and there are currently no well-validated selective agonists or antagonists that can be used as definitive pharmacological tools. No approved drug or clinical-stage therapeutic targeting GPR152 is currently available. Overall, GPR152 represents a highly unexplored orphan GPCR whose ligand discovery and pharmacological characterization could reveal new opportunities for CNS and metabolic drug discovery. For more information on GPR152 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

GPR152 is an orphan class A GPCR for which the endogenous ligand, physiological signaling pathway and pharmacological function remain largely unresolved. The receptor is predominantly expressed in... read more »
Close window
GPR152 Receptor Antibodies
GPR152 is an orphan class A GPCR for which the endogenous ligand, physiological signaling pathway and pharmacological function remain largely unresolved. The receptor is predominantly expressed in the central nervous system, with detectable expression in several brain regions and particularly in neuronal populations involved in metabolic and neuroendocrine regulation. GPR152 has also been detected in peripheral tissues, although its expression outside the CNS is comparatively poorly characterized. Available studies suggest that the receptor may couple to Gi/o and/or Gq/11 proteins, but these signaling assignments have not been sufficiently validated. Functional evidence indicates that GPR152 may participate in the regulation of neuronal signaling, energy homeostasis and endocrine functions, although a definitive physiological role has not yet been established. Genetic and expression studies have generated interest in GPR152 in the context of metabolic disorders and potentially CNS diseases, but the available evidence remains preliminary. No endogenous ligand has been conclusively identified, and there are currently no well-validated selective agonists or antagonists that can be used as definitive pharmacological tools. No approved drug or clinical-stage therapeutic targeting GPR152 is currently available. Overall, GPR152 represents a highly unexplored orphan GPCR whose ligand discovery and pharmacological characterization could reveal new opportunities for CNS and metabolic drug discovery. For more information on GPR152 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

Recently viewed